Benign Prostatic Hyperplasia – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Benign Prostatic Hyperplasia – Pipeline Review, H1 2018’, provides an overview of the Benign Prostatic Hyperplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia

– The report reviews pipeline therapeutics for Benign Prostatic Hyperplasia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Benign Prostatic Hyperplasia therapeutics and enlists all their major and minor projects

– The report assesses Benign Prostatic Hyperplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AndroScience Corp

Aphios Corp

Aquestive Therapeutics

Astellas Pharma Inc

BCWorld Pharm Co Ltd

Biolab Farmaceutica Ltda

Chong Kun Dang Pharmaceutical Corp

Curadis GmbH

Dongkook Pharmaceutical Co Ltd

GemVax & KAEL Co Ltd

Health Ever Bio-Tech Co Ltd

Jeil Pharmaceutical Co Ltd

Kissei Pharmaceutical Co Ltd

MEI Pharma Inc

Meiji Seika Pharma Co Ltd

Mezzion Pharma Co Ltd

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

OPKO Health Inc

SK Chemicals Co Ltd

Sophiris Bio Inc

Sun Pharma Advanced Research Company Ltd

XuanZhu Pharma Co Ltd

Yuyu Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Benign Prostatic Hyperplasia - Overview

Benign Prostatic Hyperplasia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Benign Prostatic Hyperplasia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development

AndroScience Corp

Aphios Corp

Aquestive Therapeutics

Astellas Pharma Inc

BCWorld Pharm Co Ltd

Biolab Farmaceutica Ltda

Chong Kun Dang Pharmaceutical Corp

Curadis GmbH

Dongkook Pharmaceutical Co Ltd

GemVax & KAEL Co Ltd

Health Ever Bio-Tech Co Ltd

Jeil Pharmaceutical Co Ltd

Kissei Pharmaceutical Co Ltd

MEI Pharma Inc

Meiji Seika Pharma Co Ltd

Mezzion Pharma Co Ltd

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

OPKO Health Inc

SK Chemicals Co Ltd

Sophiris Bio Inc

Sun Pharma Advanced Research Company Ltd

XuanZhu Pharma Co Ltd

Yuyu Pharma Inc

Benign Prostatic Hyperplasia - Drug Profiles

(alfuzosin hydrochloride ER + tadalafil) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(dutasteride + tadalafil) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(finasteride + tadalafil) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(solifenacin + tamsulosin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(tadalafil + tamsulosin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASC-JM.X2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUS-131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCWPE-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-1447 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexapotide triflutate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KKM-1202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-1AD3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCS-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7300243 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-8430506 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPK-88004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-0131632 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silodosin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sperol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

talaporfin sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tertomotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

topsalysin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-5849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YY-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Benign Prostatic Hyperplasia - Dormant Projects

Benign Prostatic Hyperplasia - Discontinued Products

Benign Prostatic Hyperplasia - Product Development Milestones

Featured News & Press Releases

May 02, 2018: Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco May 20

Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia

Apr 10, 2018: New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology

Mar 22, 2018: FDA Grants Fee Waiver for Tamsulosin DRS New Drug Application

Mar 01, 2018: Symposium and Panel Discussion on Nymox Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3

Feb 05, 2018: Nymox Announces US NDA for Fexapotide for BPH

Jan 30, 2018: Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology

Nov 27, 2017: OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy

Nov 13, 2017: Veru Announces Tamsulosin DRS Bioequivalence Clinical Trial Results

Nov 07, 2017: Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana

Oct 13, 2017: Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah

Oct 10, 2017: Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12

Sep 25, 2017: Nymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting

Sep 15, 2017: Mayne Pharma Adds Urorec (silodosin) Capsules to Its Australian Portfolio

Sep 14, 2017: Nymox Announces New Symposium for Company’s BPH Drug at American Urological Association Meeting October 5

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Benign Prostatic Hyperplasia – Pipeline by AndroScience Corp, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Aphios Corp, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Aquestive Therapeutics, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Astellas Pharma Inc, H1 2018

Benign Prostatic Hyperplasia – Pipeline by BCWorld Pharm Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Biolab Farmaceutica Ltda, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Curadis GmbH, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by GemVax & KAEL Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Health Ever Bio-Tech Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by MEI Pharma Inc, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Mezzion Pharma Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Nymox Pharmaceutical Corp, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by OPKO Health Inc, H1 2018

Benign Prostatic Hyperplasia – Pipeline by SK Chemicals Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Sophiris Bio Inc, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by XuanZhu Pharma Co Ltd, H1 2018

Benign Prostatic Hyperplasia – Pipeline by Yuyu Pharma Inc, H1 2018

Benign Prostatic Hyperplasia – Dormant Projects, H1 2018

Benign Prostatic Hyperplasia – Dormant Projects, H1 2018 (Contd..1), H1 2018

Benign Prostatic Hyperplasia – Dormant Projects, H1 2018 (Contd..2), H1 2018

Benign Prostatic Hyperplasia – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports